How long does a reconstituted peptide vial last in the fridge?
What approved labels state as in-use periods after first use, what USP assigns when no stability study exists, and what was not found for retatrutide.
Research use only. This page provides scientific background and community-report context. Every compound sold here is supplied strictly for in-vitro research, not for administration to a person or animal. This page is not an application protocol. Nothing here is a recommendation or medical advice.
TL;DR: a label period is specific to its formulation
The question people actually type: how long does a reconstituted peptide vial last in the fridge?
What the published data say: approved in-use periods belong to named finished medicines; USP assigns defaults for compounded preparations under specified conditions. Neither supplies a measured retatrutide storage window. [EMA Suliqua assessment report; USP BUD fact sheet]
What the documented search did not identify: no retatrutide in-use or reconstituted-solution stability study was identified in the PubMed search retatrutide reconstitution OR retatrutide in-use storage, which returned 0 hits on 12 Sept 2026.
What research communities report: in the Reddit corpus we track, 270 question posts in 12 months and 4 in the 4 to 12 Sept 2026 window matched language about reconstitution, refrigeration and duration or stability. These are reports, not evidence of stability or frequency outside that corpus.
What does an approved label mean by an in-use period?
An approved in-use period describes a named finished medicine and reflects the regulator's assessment of its submitted stability package. The EMA assessment for Suliqua explicitly links the submitted package to a shelf life of 24 months at 2°C to 8°C and an in-use period of 14 days below 30°C. Those are regulator-accepted periods for Suliqua pens, not transferable windows for research material. [EMA/800280/2016, p. 18]
The distinction matters because “peptide in a fridge” does not identify the formulation whose stability was evaluated. The approval belongs to that finished product. It does not establish the same period for another molecule dissolved in bacteriostatic water. [EMA Suliqua assessment report; Bacteriostatic Water for Injection USP, PRECAUTIONS]
Which periods appear in approved labels after first use?
Approved labels report different in-use periods for different finished medicines. The US Ozempic label states 56 days after first use at controlled room temperature, 15°C to 30°C. The EU Wegovy product information states 6 weeks during use below 30°C or refrigerated at 2°C to 8°C. Both contain semaglutide, but each statement belongs to its named pen and label. [Ozempic US PI, section 16; Wegovy EPAR product information, “During use”]
For other approved medicines, the Victoza US label states 30 days after first use at controlled room temperature, 15°C to 30°C; Forteo's instructions name 28 days after first use. The Mounjaro US label gives its multi-dose vial a limit of 30 days after first use, alongside a total room-temperature limit and a dose-count cap. The first-use limit alone is therefore an incomplete description of that label. [Victoza US PI, section 16; Forteo US PI, IFU; Mounjaro US PI, Medication Guide]
PeptidesDirect does not sell semaglutide (Ozempic, Wegovy). PeptidesDirect does not sell liraglutide (Victoza). PeptidesDirect does not sell teriparatide (Forteo). PeptidesDirect does not sell tirzepatide (Mounjaro). PeptidesDirect does not sell Suliqua.
What does USP assign without a validated stability study?
USP assigns default beyond-use dates within defined compounding categories; these are not measurements of an individual peptide's stability. The sterile-preparation defaults differ by preparation setting and temperature. [USP <797>, 2022 revision, BUD fact sheet, p. 3]
- Refrigerator beyond-use date
- At most 24 hours
- Comparator: controlled room temperature
- At most 12 hours
- Refrigerator beyond-use date
- 10 days
- Comparator: controlled room temperature
- 4 days
These entries describe the specified USP categories, not a classification automatically conferred by adding preserved water. The nonsterile chapter separately lists 14 days for nonpreserved aqueous forms versus 35 days for preserved aqueous forms at water activity at or above 0.60. Those nonsterile defaults do not establish an injectable solution's storage period. [USP <797> and <795>, 2022 revisions, BUD fact sheet, pp. 2 and 3]
The familiar 28-day opened multi-dose convention is a separate CDC statement, dated from opening or puncture unless the manufacturer specifies another date. It concerns the opened container, not a measured retatrutide degradation curve. [CDC, Clinical Safety Considerations]
What does bacteriostatic water contribute?
Bacteriostatic water contributes a preservative, but its label supplies no storage period for a drug dissolved in it. The reference label describes water containing 0.9% or 1.1% benzyl alcohol in a multiple-dose container. Its precautions defer storage of reconstituted drug solutions to the manufacturer of the dissolved drug. [Bacteriostatic Water for Injection USP, DESCRIPTION and PRECAUTIONS]
Our published bacteriostatic-water FAQ describes a convention of 28 days from first puncture at 2°C to 8°C. That is our published convention for the water container. The external attribution for the opened multi-dose rule here is CDC; it does not validate the stability of the resulting peptide solution. [PeptidesDirect bacteriostatic-water FAQ, retrieved 12 Sept 2026; CDC, Clinical Safety Considerations]
What chemistry matters, and what remains unknown for retatrutide?
Published formulation research documents degradation and physical instability, while the documented searches identified no reconstituted-retatrutide stability result. Li and colleagues studied model decapeptides and reported temperature-dependent degradation; Merutka and colleagues reported precipitation after reconstitution of teriparatide within 2 to 4 weeks, varying with concentration and temperature. These findings concern those experimental formulations. [PMID 19395214; PMID 26620825]
A freeze-thaw experiment on a monoclonal antibody (mAb-1, fast-freeze and slow-thaw condition) reported aggregate content of 0.1% at baseline, 4.3% after 1 cycle and 12.9% after 3 cycles. Its material was an antibody, not a peptide or retatrutide. [Jain et al., PMID 34059716, Table 4]
On 12 Sept 2026, PubMed retatrutide AND (stability OR reconstitution OR storage) returned 6 hits, none reporting reconstituted-solution stability. ClinicalTrials.gov returned 34 retatrutide studies, none a stability or storage study. No regulator-published retatrutide in-use period was identified. There is no human in-use stability result in these searches.
Our published retatrutide guidance treats the material as refrigerated at 2°C to 8°C, use-within-30-days and no-refreeze. This is a published convention, not an experimentally measured property of reconstituted retatrutide. The distinction is the answer to the fridge question: a convention supplies a stated window; these searches supply no validation of that window. [PeptidesDirect retatrutide FAQ, retrieved 12 Sept 2026]
Products mentioned
The listed research materials discussed on this page are retatrutide and bacteriostatic water.
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Supplied as a lyophilized powder for in-vitro research, with a batch-specific third-party certificate of analysis.
USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, pH 6.2 to 6.4) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
Sources
- DailyMed. Ozempic US PI, section 16. adec4fd2-6858-4c99-91d4-531f5f2a2d79.
- EMA. Wegovy EPAR product information, “During use”.
- DailyMed. Victoza US PI, section 16. 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4.
- DailyMed. Forteo US PI, IFU. aae667c5-381f-4f92-93df-2ed6158d07b0.
- DailyMed. Mounjaro US PI, Medication Guide. d2d7da5d-ad07-4228-955f-cf7e355c8cc0.
- EMA. Suliqua EPAR assessment report. EMA/800280/2016, p. 18.
- USP. 2022 revision. USP <797> and <795>, USP BUD fact sheet, pp. 2 and 3. https://mbp.ms.gov/sites/default/files/2023-03/USP_Compounding_BUD_Fact_Sheet.pdf
- CDC. Injection Safety, Clinical Safety Considerations. https://www.cdc.gov/injection-safety/hcp/clinical-safety/
- DailyMed. Bacteriostatic Water for Injection USP, DESCRIPTION and PRECAUTIONS. 87d6e9dc-fe3b-4593-ac9a-d7493d1959c7.
- Li N et al. J Pharm Biomed Anal. 2009. PMID 19395214.
- Merutka G et al. Eur J Pharm Biopharm. 2016. PMID 26620825.
- Jain K et al. Sci Rep. 2021. Table 4. PMID 34059716; PMC8166975.
- PubMed. Retatrutide in-use, reconstitution and storage searches documented on 12 Sept 2026; search strings and counts reported above.
- ClinicalTrials.gov v2. Search
retatrutide, verified 12 Sept 2026. - PeptidesDirect. Product FAQ retatrutide, retrieved 12.09.2026. peptidesdirect.io.
- PeptidesDirect. Product FAQ bacteriostatic-water, retrieved 12.09.2026. peptidesdirect.io.
Research use only. Every compound sold here is supplied strictly for in-vitro research, not for human or animal administration. Nothing in this article is an application protocol or medical advice.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include VAT, the rate depends on the destination country; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.